Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses

Background Despite advances with therapies targeting the PD-1/PD-L1 pathway, many patients are refractory or relapse following treatment. LAG-3 expression on exhausted T cells and T-regulatory cells (Tregs) in the tumor may be responsible for this resistance and provides a rationale for co-treatment...

Full description

Bibliographic Details

Published in:	Cancer research (Chicago, Ill.) Vol. 78; no. 13_Supplement; p. 2719
Main Authors:	Kraman, Matthew, Fosh, Natalie, Kmiecik, Katarzyna, Everett, Katy, Zimarino, Carlo, Faroudi, Mustapha, Wydro, Mateusz, Koers, Alexander, Young, Lesley, Gliddon, Daniel, Morrow, Michelle, Doody, Jacqueline, Tuna, Mihriban, Brewis, Neil
Format:	Journal Article
Language:	English
Published:	01-07-2018
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!